GLS

Alivus Life Sciences Ltd.

NSE: ALIVUS

BSE: 543322

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,329.80+4.6 (+0.35%)

7 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

94.5 / 100

Value Score

39.6 / 100

Price Momentum Score

89.2 / 100

QVM Score

93.7 / 100

Key Metrics

Market Cap

16326.10

P/E (TTM)

27.07

P/B

4.90

P/S (TTM)

6.30

EV/EBITDA

18.61

CAPE (5Y)

33.00

ROE (TTM)

18.36

ROCE (TTM)

23.05

ROA (TTM)

15.27

Avg 3Y ROE

19.43

Earnings 3Y CAGR

6.76

Sales 3Y CAGR

4.81

Sales 5Y CAGR

6.24

Debt/Equity

0.02

Consensus TP

1352.50

Strong Buy %

50.00

Promoter Holding

74.87

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Alivus Life Sciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 89.2 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

89.2 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 2.9% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable ROE

The company reported strong ROE of 18.36% for 12-month ended 30 Jun 2026 and ROE declined marginally by -50 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 29.25% for 12-month ended 30 Jun 2026 and operating margin improved by 291 bps from 1 year ago

What is Operating profit margin?

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 21.6% for 12-month ended 30 Jun 2026 and the growth was 8.32 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.02 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 7.93% for 12-month ended 30 Jun 2026 and the growth was 4.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.93

Value 7.93

-42.89239.3

Low dividend yield

The company has a low dividend yield of 0.38%

What is Dividend yield?

Neutral

Stock appears expensive but is at a discount to industry median P/E

PE TTM of 27.07 indicates that the stock is expensive on a standalone basis but discount to industry median P/E is decent at -11.51%

What is P/E Ratio?

Median: 30.59

Value 27.07

0.33286.35

Company's earnings are of moderate quality

Earnings quality score of 55.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

55.9 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Alivus Life Sciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Alivus Life Sciences Ltd. Shareholding Pattern

Quarterly breakdown of Alivus Life Sciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	82.84	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	75.00	75.00	74.99	74.94	74.91	74.91	74.87	74.87
Indian Promoter	82.84	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	82.85	75.00	75.00	74.99	74.94	74.91	74.91	74.87	74.87
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	8.49	8.79	8.68	8.37	6.83	4.55	3.29	3.85	5.02	5.31	6.41	6.39	12.01	11.60	11.76	12.03	12.31	12.21	12.57	12.72
Mutual Funds / UTI	0.30	0.32	0.50	0.71	0.71	-	-	0.52	0.38	0.59	0.93	1.01	2.82	3.23	3.59	4.06	3.87	5.44	5.63	5.65
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.07	0.07	0.00	0.00	0.15	0.00	0.00	0.00	0.08	0.22	0.22	0.18	0.24	0.27	0.27	0.27
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	8.03	8.32	8.12	7.58	6.04	4.45	3.28	3.27	4.39	4.57	5.01	4.81	7.85	6.74	6.57	6.42	6.84	5.08	5.30	5.54
Other Institutions	0.16	0.30	0.12	0.15	0.01	0.01	0.00	0.06	0.11	0.15	0.48	0.56	1.26	1.41	1.38	1.38	1.36	1.42	1.37	1.26
Non-Institution	8.67	8.36	8.47	8.78	10.31	12.60	13.86	13.30	12.12	11.84	10.73	10.76	12.99	13.40	13.25	13.03	12.78	12.88	12.56	12.41
Bodies Corporate	0.43	0.36	0.32	0.32	0.36	1.96	2.02	2.09	2.04	1.95	0.88	0.87	1.39	1.41	1.79	1.72	1.62	1.65	1.57	1.27
Others (incl. Retail) No. of shareholders	8.24 2,79,948	8.00 2,53,391	8.15 2,38,273	8.46 2,33,235	9.95 2,31,880	10.64 2,25,402	11.84 2,22,536	11.21 2,07,883	10.08 1,98,332	9.89 1,85,126	9.85 1,55,582	9.89 1,48,646	11.60 1,43,076	11.99 1,45,765	11.46 1,40,899	11.31 1,37,509	11.16 1,34,664	11.23 1,31,772	10.99 1,27,037	11.14 1,24,608

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.4%	90 / 250
2	Nifty Total Market	0.02%	559 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Alivus Life Sciences Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Glenmark Pharmaceuticals Limited Promoter	March-2024	Off Market (Disposal) 13th Mar 2024	27.84 %	₹ 597.99	2.45 cr	₹ 1465.41 cr
Nirma Limited Promoter	March-2024	Off Market (Acquisition) 13th Mar 2024	55.00 %	₹ 598.59	2.45 cr	₹ 1466.88 cr
Glenmark Pharmaceuticals Limited Promoter	March-2024	Off Market (Disposal) 7th Mar 2024	82.84 %	₹ 597.99	6.74 cr	₹ 4029.88 cr
GLENN SALDANHA Promoter Group	November-2021	Market Purchase (Acquisition) 17th Nov 2021	0.00 %	₹ 640.77	295.00	₹ 1.89 lac
GLENN SALDANHA Promoter Group	November-2021	Market Purchase (Acquisition) 17th Nov 2021	0.00 %	₹ 643.19	7.50 k	₹ 48.27 lac

Corporate Actions

History of Alivus Life Sciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 5/share
Record date: 1st Sep 2026Ex-date: 1st Sep 2026
Announced on: 14th May 2026
Dividend₹ 5/share
Record date: 1st Sep 2025Ex-date: 1st Sep 2025
Announced on: 15th May 2025
Dividend₹ 22.50/share
Record date: 17th Oct 2023Ex-date: 17th Oct 2023
Announced on: 4th Oct 2023
Dividend₹ 21/share
Record date: 24th Mar 2023Ex-date: 24th Mar 2023
Announced on: 14th Mar 2023
Dividend₹ 10.50/share
Record date: 16th Sep 2022Ex-date: 15th Sep 2022
Announced on: 20th Apr 2022

Company Profile

Overview of Alivus Life Sciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range o...

Key personnel

Mr. Tushar Mistry

Chief Financial Officer, Senior Vice President

Mr. Sumantra Mitra

Senior Vice President - Human Resources, Head - Human Resources

Mr. Navin Kumar Agrawal

Senior Vice President - Quality, Head - Corporate Quality

Mr. Mathew George

Senior Vice President - Regulatory Affairs, Head - Regulatory Affairs

Mr. Rudalf Joseph Corriea

Company Secretary, Compliance Officer

Dr. Palle V.R Acharyulu

Group Vice President, Head - Research and Development

Mr. Hiren Karsanbhai PatelD

Non-Executive Non-Independent Chairman of the Board

Dr. Yasir Yusufali RawjeeD

Chief Executive Officer, Managing Director, Executive Director

View all

Incorporated on

23 Jun 2011

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

06 Aug 2021

Free Float

2,93,71,163

Website

https://www.alivus.com/

Phone no.

+912268297979

Address

4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), MUMBAI, 400099, India

Frequently Asked Questions

What is the current share price of Alivus Life Sciences Ltd.?

The current share price of Alivus Life Sciences Ltd. is ₹ 1,329.80 as of 7 Aug 2026.

What is the market capitalisation of Alivus Life Sciences Ltd.?

The market capitalisation of Alivus Life Sciences Ltd. stands at ₹ 16,326.10 Cr.

What is the PE ratio of Alivus Life Sciences Ltd.?

The Price-to-Earnings (PE) ratio of Alivus Life Sciences Ltd. is 27.07 as of the latest trailing twelve months data.

What is the ROE and ROCE of Alivus Life Sciences Ltd.?

Alivus Life Sciences Ltd. has a Return on Equity (ROE) of 18.36% and a Return on Capital Employed (ROCE) of 23.05% as per the latest financial reports.

What is the 52-week high and low of Alivus Life Sciences Ltd.?

The 52-week high of Alivus Life Sciences Ltd. is - and the 52-week low is -.

What is the dividend yield of Alivus Life Sciences Ltd.?

The dividend yield of Alivus Life Sciences Ltd. is 0.38% based on the current market price.

What is the FII and DII holding in Alivus Life Sciences Ltd.?

Foreign Institutional Investors (FII) hold 5.54%, Domestic Institutional Investors (DII) hold 5.92% and retail/public investors hold 11.14% of Alivus Life Sciences Ltd. shares.

What sector does Alivus Life Sciences Ltd. belong to?

Alivus Life Sciences Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Alivus Life Sciences Ltd. with a consensus target price of ₹ 1,352.50, implying 1.71% upside from current levels.

What is the beta of Alivus Life Sciences Ltd.?

The beta of Alivus Life Sciences Ltd. is 0.62, indicating its price volatility relative to the broader market. Over the past 1 year, Alivus Life Sciences Ltd. has delivered an absolute return of 26.61%.

What is the RSI of Alivus Life Sciences Ltd.?

The 14-day Relative Strength Index (RSI) of Alivus Life Sciences Ltd. is 73.00, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Alivus Life Sciences Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Alivus Life Sciences Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions